Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM

Edmond DE Rothschild Holding S.A. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 74,350 shares of the medical device company’s stock, valued at approximately $5,007,000.

Several other institutional investors also recently bought and sold shares of the stock. Reflection Asset Management purchased a new stake in DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom in the 1st quarter valued at $25,000. MCF Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at $32,000. Wellington Grp LLC lifted its stake in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC purchased a new stake in DexCom during the fourth quarter worth $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM opened at $89.88 on Thursday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $91.96. The stock has a market cap of $33.92 billion, a PE ratio of 35.53, a P/E/G ratio of 1.51 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average of $76.85 and a 200 day moving average of $70.67.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.48 EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DXCM shares. Robert W. Baird set a $105.00 price objective on shares of DexCom in a report on Friday, July 31st. TD Cowen reissued a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Truist Financial set a $93.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $88.71.

Insider Buying and Selling

In other DexCom news, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the sale, the director owned 48,852 shares of the company’s stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,035 shares of company stock worth $5,446,673 in the last three months. Company insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.